Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer

阿帕蒂尼 医学 内科学 肿瘤科 实体瘤疗效评价标准 肺癌 养生 临床终点 无进展生存期 队列 癌症 化疗 外科 胃肠病学
作者
Guanghui Gao,Jun Zhao,Shengxiang Ren,Yina Wang,Gongyan Chen,Jianhua Chen,Kangsheng Gu,Renhua Guo,Yueyin Pan,Quanren Wang,Weixia Li,Xinfeng Yang,Caicun Zhou
出处
期刊:Annals of Translational Medicine [AME Publishing Company]
标识
DOI:10.21037/atm-21-4792
摘要

Limited data are available for the combination regimen of anti-programmed cell death protein 1 (PD-1) inhibitor and anti-angiogenic agents as second-line therapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC), especially in patients with squamous NSCLC. This study assessed the efficacy and safety of camrelizumab plus apatinib (a vascular endothelial growth factor receptor 2 inhibitor) as second-line treatment in patients with advanced squamous NSCLC.In the Cohort 3 from a phase II dose-expansion trial, patients with advanced non-central squamous NSCLC who were immunotherapy naïve and had failed prior first-line platinum-based chemotherapy received 200 mg of camrelizumab intravenously every 2 weeks plus oral apatinib at the recommended dose of 250 mg once daily. The primary endpoint was objective response rate (ORR) assessed by the investigators as per the Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1.Cohort 3 was prematurely terminated because of slow accrual after 25 patients with advanced squamous NSCLC had been enrolled between 10 October 2018, and 3 March 2019. At the data cutoff date of 12 June 2020, the median follow-up was 13.3 (range, 1.6 to 19.2) months. Among all 25 participants, the ORR was 32.0% (95% CI: 14.9% to 53.5%), the clinical benefit rate was 44.0% (95% CI: 24.4% to 65.1%), and the disease control rate (DCR) was 84.0% (95% CI: 63.9% to 95.5%). Median progression-free survival (PFS) was 6.0 (95% CI: 3.5 to 8.1) months, and median overall survival (OS) was 13.3 (95% CI: 6.4 to 18.8) months. Furthermore, clinical benefits from this combination regimen were evident across all tumor PD ligand 1 (PD-L1) expression subgroups. The most common treatment-related adverse events (TRAEs) of grade 3 or higher were hypertension (44.0%) and palmar-plantar erythrodysesthesia (16.0%). As reported by the investigators, 3 participants (12.0%) died due to TRAEs (interstitial pneumonia, hemorrhage, and unknown reason; n=1 each, 4%).Camrelizumab plus apatinib as second-line therapy showed satisfactory antitumor activity in patients with non-central squamous NSCLC, regardless of tumor PD-L1 expression. Camrelizumab plus apatinib had a manageable safety profile in this patient population, and the toxic reactions observed were generally consistent with those in previously reported studies. Interstitial pneumonia and hemorrhage are important risks requiring careful monitoring and prompt intervention.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
kkk发布了新的文献求助10
1秒前
彭于晏的应助被佚名采纳,获得10
1秒前
深情安青的应助被Dugarrygana采纳,获得10
1秒前
2499297293发布了新的文献求助20
1秒前
等待geduo完成签到 ,获得积分10
1秒前
stella完成签到 ,获得积分10
1秒前
2秒前
2秒前
2秒前
2秒前
2秒前
3秒前
salute_sang完成签到,获得积分10
3秒前
科研通AI6.3的应助被白色采纳,获得10
3秒前
3秒前
yujihaiasdfg发布了新的文献求助10
4秒前
4秒前
4秒前
5秒前
LW90完成签到,获得积分10
5秒前
yuxing发布了新的文献求助10
5秒前
6秒前
lulu发布了新的文献求助10
6秒前
6秒前
6秒前
7秒前
柴六斤发布了新的文献求助10
7秒前
无花果的应助被2499297293采纳,获得10
7秒前
8秒前
梅特福斯完成签到,获得积分10
8秒前
8秒前
科目三的应助被活力定帮采纳,获得10
8秒前
Nasser发布了新的文献求助30
9秒前
9秒前
9秒前
sqqx发布了新的文献求助10
9秒前
搜集达人的应助被arT采纳,获得10
9秒前
超帅傲白发布了新的文献求助10
10秒前
小桃完成签到,获得积分10
10秒前
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175653
求助须知:如何正确求助?哪些是违规求助? 9567273
关于积分的说明 21791766
捐赠科研通 7770183
什么是DOI,文献DOI怎么找? 3431873
关于科研通互助平台的介绍 2556250
邀请新用户注册赠送积分活动 2477299